NZYM B Novozymes A/S Class B

Novozymes is combining cutting-edge science and business expertise to help feed the world sustainably

Novozymes is combining cutting-edge science and business expertise to help feed the world sustainably

To feed a growing population, Novozymes is inviting all interested parties to help co-create and innovate the future of sustainable protein. By combining science with business expertise Novozymes wants to rethink how protein is made and sourced by enabling a new and progressive industry to provide sustainable nutrition. 

COPENHAGEN, DENMARK – 21 September, 2021 – As the U.N. Food System Summit sets the stage to bring about tangible, positive changes to the world’s food systems, Novozymes, the world leader in biological solutions, wants to rethink the way we manufacture and source protein. Novozymes announces the launch of the Myco-protein Innovation Call – a global platform to cultivate new business collaborations to scale up the most promising innovations and ideas around how to use fungi as a source of protein.

  • “Realizing the importance of rethinking how we expand the adoption of plant-based protein and how we meet an increasing demand for sustainable nutrition, Novozymes is launching this global platform to help transform the future of food though the power of fungi and mycelium. Transforming our global food systems at scale will require radical new ways of working, bringing together the most cutting-edge scientific and business expertise from across industries and sectors – and this is what the Myco-protein Innovation Call is all about. We want to rethink and advance protein to find innovative ways to help feed the world sustainably,” says Amy Louise Byrick, Executive Vice President of Strategy & Business Transformation at Novozymes.

Within recent years, the global focus on myco-protein has risen significantly, and the increased awareness of a need for new sources of protein has brought attention to the potential of fungal mycelium. Its versatility is vast and has the potential to be used among others for whole-cut meat analogues, vegan bacon, tempeh, or even cream cheese. Despite neither the technology nor fermentation being new, innovative ways of utilizing the power of fungi for food applications is accelerating fast. 

Paving the way for innovative business collaborations

Novozymes has created a space where companies focused on new ways of working with myco-proteins can benefit from synergies across themes and functions. The Innovation Call invites start-ups, research centres, academics, corporates, NGOs, and public entities focused on new ideas within alternative proteins – and more specifically fungal mycelium – in food ingredients and products to apply to co-create and innovate the future of sustainable protein.

  • “As a biotech powerhouse, Novozymes can unlock significant value by building on decades of experience within fungal mycelium,” says Byrick. “We want to leverage this expertise around microbial fermentation and fungi to support the most promising innovations and ideas in the space of protein ingredients for food applications."

At a time of accelerating demand across the protein space, Novozymes is strengthening its commitment to the area of Advanced Protein Solutions, built on a powerful portfolio of biotech solutions in the food and beverage areas.  Recently, the company entered a long-term contract with a key player in the plant-based industry, marking an important milestone in Novozymes’ strategy, Better business with biology.



The Myco-Protein Innovation Call is a new commitment to the area, designed as an opportunity to leverage Novozymes’ global scientific and business leadership to support emerging innovations in the myco-protein space, and together build the future of food.

For more information and to submit your application, visit the .

Fact Box:
  • The Innovation Call invites startups, research centers, academics, corporates, NGOs, and public entities focused on new ways of working with fungal mycelium in food ingredients and products to apply.
  • The Myco-Protein Innovation Call opens for applications on Sept 21. Applications will be accepted on an on-going basis, with two key dates set for application review by the Novozymes team: November 15th, 2021, and January 31st, 2022.
  • Selected companies/solutions will be invited to co-design a formal collaboration, with Novozymes seeking to serve as a key collaboration partner and catalyst in scaling up the solution together.
  • Potential opportunities for these collaborations include access to scientific, business, R&D experts, and labs facilities; access to distribution channels, potential investment/join-ventures; and formal partnerships with Novozymes. 

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future.

We call it Rethink Tomorrow.  



NASDAQ OMX: NZYM-B • 6,200 employees • DKK 14,5 billion turnover • 30+ industries • 700+ products



Media Relations
   
Lina Danstrup,

Head of Media Relations

Phone:





 



Frederik Bjørndal

Head of Communications, NA

Phone:

   
     
Investor Relations    
Tobias Cornelius Björklund

Phone:

   

Attachment



EN
21/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

 PRESS RELEASE

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

 PRESS RELEASE

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch